Real-World Major Adverse Cardiovascular Events of Nicorandil and Nitrate in Coronary Heart Disease in Central China: A Retrospective Cohort Study

Real-World Major Adverse Cardiovascular Events of Nicorandil and Nitrate in Coronary Heart Disease in Central China: A Retrospective Cohort Study

Objective:. Residual cardiovascular risk in patients with coronary heart disease (CHD) still needs to be addressed in real-world practice. This study aimed to examine the clinical effectiveness of nicorandil and nitrate in addition to optimal treatment for CHD patients. Methods:. This retrospective...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ping Li, Juan Chen, Na Li, Xiang You, Lan Shen, Ning Zhou
Format:	Article
Language:	English
Published:	Wolters Kluwer Health/LWW 2023-09-01
Series:	Cardiology Discovery
Online Access:	http://journals.lww.com/10.1097/CD9.0000000000000092
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Association between the atherogenic index of plasma and major adverse cardiovascular events in patients with premature coronary artery disease
by: Xiangzhen Ran, et al.
Published: (2025-06-01)

Cardiac scoring systems, coronary artery disease and major adverse cardiovascular events: A scoping review
by: Preesha Premsagar, et al.
Published: (2023-08-01)

Effect of levothyroxine on major adverse cardiovascular events in patients with hypothyroidism and cardiovascular disease
by: Lijia Liu, et al.
Published: (2025-08-01)

Impact of Pre-Diabetes on the Rate of Major Adverse Cardiovascular Events in Patients Undergoing Coronary Artery Bypass Grafting
by: A. N. Sumin, et al.
Published: (2018-11-01)

Validation of Medication Proxies for the Identification of Hospitalizations for Major Adverse Cerebro-Cardiovascular Events
by: Steenhuis D, et al.
Published: (2025-03-01)

Combining echocardiography with carotid ultrasound parameters in predicting major adverse cardiovascular events among older individuals with coronary artery disease
by: Tianli Jia, et al.
Published: (2025-07-01)

Frailty, Pitavastatin, and Major Adverse Cardiovascular Events Among People With HIV
by: Kristine M. Erlandson, MD, MS, et al.
Published: (2025-09-01)

Metabolic syndrome with mortality and major adverse cardiovascular events in an elderly population
by: Shailendra Kumar Karn, et al.
Published: (2025-05-01)

Effects of High- or Moderate-intensity Rosuvastatin on 1-year Major Adverse Cardiovascular Events Post-percutaneous Coronary Intervention
by: Morteza Chehrevar, et al.
Published: (2022-11-01)

Safety assessment of temozolomidee: real-world adverse event analysis from the FAERS database
by: Yu Liu, et al.
Published: (2025-08-01)

Predictive values of serum FGF21 and SCUBE-1 in predicting major adverse cardiovascular events in maintenance hemodialysis patients
by: Xu Mei, et al.
Published: (2025-03-01)

Multimorbidity in Atherosclerotic Cardiovascular Disease and Its Associations With Adverse Cardiovascular Events and Healthcare Costs: A Real-World Evidence Study
by: Dingwei Dai, et al.
Published: (2024-03-01)

Updating understanding of real-world adverse events associated with omeprazole.
by: Jijun Zhang, et al.
Published: (2025-01-01)

Triglyceride-Glucose Index Predicts Major Adverse Cardiovascular and Cerebrovascular Events in Non-Diabetic Individuals
by: Cangtuo Li, et al.
Published: (2025-07-01)

Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study
by: Bangbei Wan, et al.
Published: (2025-02-01)

Ten-year predictors of major adverse cardiovascular events in patients without angina
by: Preesha Premsagar, et al.
Published: (2023-08-01)

Major Adverse Cardiovascular Events in Patients with Melanoma Receiving Immune Checkpoint Inhibitors
by: Juan I. Ruiz, et al.
Published: (2025-04-01)

Real-world FDA database analysis unveiling cardiovascular adverse events associated with bispecific T cell engagers in multip myeloma
by: Chang Shan, et al.
Published: (2025-07-01)

Prediction of 1-Year Major Adverse Cardiovascular Events in Chronic Limb Threatening Ischemia
by: Sreekanth Vemulapalli, MD, et al.
Published: (2025-08-01)

Author Correction: Predictive model development combining CT-FFR and SYNTAX score for major adverse cardiovascular events in complex coronary artery disease
by: Weiqing Luo, et al.
Published: (2025-04-01)

Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database
by: Yu Lin, et al.
Published: (2025-08-01)

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Zhuomiao Lin, et al.
Published: (2025-08-01)

Association between residual cholesterol and vulnerable non-culprit lesions progressing to major adverse cardiovascular events
by: Fengfeng Wang, et al.
Published: (2025-08-01)

Body mass index modifies the major adverse cardiovascular and cerebral events risk of NT-proBNP in patients with acute coronary syndrome
by: Xiaoquan He, et al.
Published: (2025-03-01)

Establishment of a prediction model for major adverse cardiovascular and cerebrovascular events in prehypertensive patients
by: HE Zhi,an，LAI Jiangqiong，ZHENG Tao
Published: (2025-07-01)

Sleep disorder is associated with increased risk of major adverse cardiovascular events in patients with schizophrenia
by: Jinbo Wu, et al.
Published: (2025-07-01)

Predictors of adverse cardiovascular events in patients with coronary artery disease after percutaneous coronary intervention
by: A. V. Svarovskaya, et al.
Published: (2020-07-01)

Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database
by: Jinlong Huang, et al.
Published: (2025-04-01)

Influence of systemic immunoinflammatory index on major adverse cardiovascular events in patients with coronary heart disease with heart failure as assessed by propensity score matching
by: ZhiRong Ren, et al.
Published: (2025-08-01)

Real-World Pharmacovigilance Analysis of Adverse Events Associated with Liposomal Bupivacaine and Bupivacaine
by: Chen DX, et al.
Published: (2025-04-01)

A Machine Learning Model Integrating Tongue Image Features and Myocardial Injury Markers Predicts Major Adverse Cardiovascular Events in Patients with Coronary Heart Disease
by: Zhou M, et al.
Published: (2025-07-01)

Renal hyperfiltration as risk factor of major adverse cardiovascular events in patients with acute myocardial infarction
by: Jin Sug Kim, et al.
Published: (2025-07-01)

Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis
by: George Athanasios Karpouzas, et al.
Published: (2024-09-01)

Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality analysis based on FDA adverse event reporting system (FAERS)
by: Xiang Li, et al.
Published: (2025-06-01)

Nicorandil in clinical cardiology practice
by: article Editorial
Published: (2012-02-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab
by: Linlin Yan, et al.
Published: (2025-04-01)

Association between adjusted atherogenic index of plasma and major adverse cardiovascular events after percutaneous coronary intervention in patients with STEMI: a prospective observational study in China
by: Dong Wu, et al.
Published: (2025-08-01)

Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system
by: Wensheng Liu, et al.
Published: (2025-05-01)

Incremental predictive value of liver fat fraction based on spectral detector CT for major adverse cardiovascular events in T2DM patients with suspected coronary artery disease
by: Min Wang, et al.
Published: (2025-04-01)

Evaluation of Perioperative Major Adverse Cardiac Events in Patients with Coronary Artery Disease Undergoing Carotid Endarterectomy
by: V Krishna Narayanan Nayanar, et al.
Published: (2025-07-01)